CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY
This research trial, called COLPRIT, is looking for better ways to deal with advanced non-Hodgkin lymphomas, which are types of cancer affecting white blood cells. It involves using two special substances. The first, [68Ga]Ga-PentixaFor, helps doctors accurately see the cancer inside the body. The second, [90Y]Y-PentixaTher, is designed to deliver targeted radiation directly to the cancer cells. This is a two-part study. The first part focuses on finding the safest dose for the treatment. The second part will then look at how well this treatment shrinks or controls the cancer. It's hoped this approach could lead to more effective and precise treatments.
At a glance
What is this study about?
This study is called COLPRIT, and it's looking into new ways to treat advanced non-Hodgkin lymphomas. These are cancers that start in white blood cells called lymphocytes, which are an important part of your immune system. When cancer is 'advanced', it means it has spread or is difficult to treat with standard methods.
The researchers are testing a new approach called 'theranostics'. This word comes from 'diagnosis' (finding out what's wrong) and 'therapeutics' (treating it). It means they are using substances that can both help to pinpoint the cancer and then also treat it. For finding the cancer, they use something called [68Ga]Ga-PentixaFor. This substance attaches to certain markers on cancer cells, making them light up on special scans, so doctors can see exactly where they are. For treatment, they use [90Y]Y-PentixaTher, which is designed to deliver targeted radiation directly to these marked cancer cells, hopefully causing less damage to healthy parts of the body.
This study has two main parts. The first part (Phase I) is about finding the safest dose of the treatment, making sure it's well-tolerated by patients. Once a safe dose is found, the second part (Phase II) will look at how effective this treatment is at shrinking the cancer or stopping it from growing. They will also keep a close eye on any side effects and how patients are generally doing. This research is important because it could lead to new, more precise ways to manage advanced non-Hodgkin lymphomas.
Key takeaways
- This study is testing a new way to find and treat advanced non-Hodgkin lymphoma.
- It uses special substances that can both locate and treat cancer cells.
- The study aims to find a safe dose and see how well the treatment works.
- It's open to adults aged 18 and over, both men and women.
- Participation involves tests, treatment, and regular check-ups to monitor your health.
Who may be eligible?
To be considered for this study, you must be 18 years old or older. There is no upper age limit, meaning older adults can also take part.
This study is open to both men and women.
Apart from age and sex, specific details about your type of non-Hodgkin lymphoma and your general health would be checked by the study doctors to see if this treatment is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced non-Hodgkin lymphoma?
- Are you able to attend regular hospital visits?
- Are you prepared to potentially receive a new, experimental treatment?
What does participation involve?
If you decide to take part in this study, you'll first have a series of check-ups and tests. These tests may include scans to understand your cancer better and make sure the treatment is suitable for you. You will receive the study treatment, which involves an injection of the special substances mentioned. The doctors will closely monitor you during and after the treatment. This will involve regular visits to the hospital for blood tests, scans, and check-ups to see how you are responding to the treatment and to keep an eye on any side effects. The exact number of visits and the total duration in the study will vary for each patient, but you will be fully informed of the schedule if you decide to participate. You will have regular contact with the study team throughout.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is non-Hodgkin lymphoma?
Non-Hodgkin lymphoma is a type of cancer that starts in white blood cells called lymphocytes, which are part of your body's immune system.
What does 'advanced' cancer mean in this study?
'Advanced' means the cancer may have spread or is harder to treat with standard methods.
What is 'theranostics'?
It's a combined approach where special substances are used both to find the cancer (diagnosis) and then to treat it (therapeutics).
Will I receive radiation treatment?
Yes, part of this experimental treatment involves delivering targeted radiation directly to the cancer cells using a special substance.
Can I leave the study if I change my mind?
Yes, you can choose to stop participating in the study at any time, for any reason, without affecting your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.